Document Classification

Section Type: RESULTS

Text: With a median follow-up of 60 months, adding chemotherapy statistically significantly improved the 5-year OS rate (94. 5 % vs 85. 8 % ; HR of death = 0. 30, 95 % CI = 0. 12 to 0. 76 ; P =. 007), PFS (87. 9 % vs 77. 8 % ; HR of progression = 0. 45, 95 % CI = 0. 23 to 0. 88 ; P =. 017), and distant metastasis-free survival (94. 8 % vs 83. 9 % ; HR of distant relapse = 0. 27, 95 % CI = 0. 10 to 0. 74 ; P =. 007) ; however, there was no statistically significant difference in the 5-year locoregional relapse-free survival rate (93. 0 % vs 91. 1 % ; HR of locoregional relapse = 0. 61, 95 % CI = 0. 25 to 1. 51 ; P =. 29).